Overview of Spasmo-Mucosolvan

Property	Description
Active ingredient	Ambroxol hydrochloride and Clenbuterol hydrochloride
Form	Tablet, Syrup, Oral solution
Pharmacological class	Bronchosecretolytic combination agent
Common purpose	Easing breathing difficulty caused by spasm and thick mucus
Origin	Synthetic

The Identity and Pharmacological Class of Spasmo-Mucosolvan

Spasmo-Mucosolvan is a synthetic, fixed-dose combination (FDC) pharmaceutical preparation that is classified as a bronchosecretolytic combination agent. This designation means the medicine combines two distinct pharmacological actions—relieving spasms in the airways and clearing secretions—within a single oral formulation. This dual functional role allows the product to address concurrent issues often observed in respiratory conditions, which is essential for comprehensive airway management.

The product's classification, which includes a beta-2 adrenergic agonist component like Clenbuterol, supports its primary function of improving airflow by relaxing bronchial smooth muscle. This approach is clinically recognized for providing more comprehensive respiratory relief than monotherapy in cases where both bronchospasm and hyperviscosity are present.

Composition: A Dual-Action Synthetic Formula

The active core of Spasmo-Mucosolvan consists of two distinct synthetic compounds: Ambroxol hydrochloride and Clenbuterol hydrochloride. These ingredients are often formulated for oral administration in multiple dosage forms, including the tablet, syrup, and oral solution. Other products containing this same combination may be marketed under similar combination names.

The Ambroxol component functions as a secretolytic agent, helping to decrease the viscosity of sticky mucus. Ambroxol is classified for its direct effect on respiratory secretions. Conversely, Clenbuterol is identified as a selective beta-2 adrenergic agonist. This strategic pairing ensures the simultaneous systemic action of both clearing secretions and relaxing the constricted smooth muscles of the airways.

General Purpose and Benefit

The general purpose of Spasmo-Mucosolvan is to provide comprehensive relief for respiratory discomfort resulting from both airway narrowing and excessive, tenacious mucus. By combining bronchodilation with mucus thinning, the medication addresses the two major physical issues—obstruction and hyperviscosity—that can impair clear breathing. A typical scenario for its use involves patients experiencing conditions where thick phlegm co-occurs with muscle spasms in the airways. This targeted dual action aids in the expulsion of secretions and the alleviation of bronchial tube constriction, helping to ease chest congestion.

What side effects are possible with Spasmo-Mucosolvan?

Possible Side Effects

Spasmo-Mucosolvan, a combination product containing ambroxol and clenbuterol (or propoxyphene in some historical/international formulations), may be associated with side effects primarily related to its components. It is essential to seek immediate medical attention if any severe reaction occurs.

Common and Uncommon Reactions (Ambroxol Component):

Most reported adverse reactions are mild, mainly affecting the gastrointestinal tract. These include:

Nausea, vomiting, and diarrhea
Digestive disorders, dry mouth, or dry throat
Altered sense of taste or numbness in the mouth/throat

Serious and Rare Reactions (Ambroxol Component):

In rare instances, severe allergic and skin reactions have been reported in connection with ambroxol, including anaphylactic reactions and severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome and toxic epidermal necrolysis. If a new skin rash or mucosal lesion appears, treatment should be stopped immediately.

Clenbuterol/Propoxyphene-Related Effects (Spasmo- or combination component):

Depending on the specific formulation, the component designed for bronchial spasm relief (such as clenbuterol or the opioid propoxyphene) may cause additional effects. For clenbuterol, these are often related to its beta-agonist activity, including tremors, nervousness, headache, and palpitations/increased heart rate. Formulations containing propoxyphene carry risks of dependency, dizziness, sedation, and potentially fatal cardiac rhythm disturbances, leading to its withdrawal from many markets.

Safety and Contraindications

This medication is typically not recommended for patients with a known hypersensitivity to the active ingredients or excipients. Caution is advised for individuals with a history of gastric ulceration. Due to limited data on safety, its use is generally not recommended during the first trimester of pregnancy or while breastfeeding. Patients with liver or kidney impairment may require dose adjustments due to altered drug clearance.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Spasmo-Mucosolvan is primarily associated with excessive effects from the Clenbuterol component, a beta-adrenergic agonist, with the potential for severe, life-threatening outcomes.

Documented Overdose Manifestations and Scope

Clinical manifestations documented in regulatory sources include pronounced signs of beta-adrenergic overstimulation: tachycardia (rapid heart rate), palpitations, muscle tremor, headache, and nervousness. The physiological systems primarily affected are the cardiovascular (arrhythmias, myocardial ischemia) and metabolic (severe hypokalemia, lactic acidosis). Overdose risk may be heightened in patients with pre-existing cardiovascular disorders. The long half-life of Clenbuterol may necessitate extended observation.

Emergency Response and Management

Regulators mandate that patients seek immediate medical attention or contact emergency services upon any suspected overdose, particularly due to the potential for severe cardiac or metabolic instability. The management procedures listed in official documents are strictly symptomatic and supportive. This approach requires continuous cardiac monitoring and the mandated correction of electrolyte imbalances, notably serum potassium. While there is no specific antidote known for the Ambroxol component, cardioselective beta-blockers may be considered in a hospital setting to address severe cardiac symptoms, with strict caution regarding potential bronchospasm.

Therapeutic Uses of Spasmo-Mucosolvan

What Spasmo-Mucosolvan Treats: Main Uses and Benefits

Spasmo-Mucosolvan is commonly used to help manage symptomatic manifestations in patients with respiratory conditions characterized by the combination of airway narrowing (spasm) and the presence of overly thick, viscid mucus. This combination therapy is commonly applied across domains involving airway diseases requiring supportive symptom management.

The combination is considered relevant for a range of conditions, including acute bronchitis, chronic bronchitis, bronchial asthma, and bronchiectasis. It is used when groups of symptoms appear suddenly or fluctuate, such as the difficulty in expectoration of phlegm and associated shortness of breath. By addressing the constricted airways and supporting the clearance of secretions, the medication may assist with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.

This approach is also relevant when supportive symptom management is appropriate in specific clinical scenarios, such as addressing postoperative difficulty in phlegm expectoration.

Quick Fact: Relief for Dual Airway Issues
This combination is used when symptoms are driven by the co-existence of airway spasm and mucus hyperviscosity, assisting with symptomatic relief related to breathing difficulty and impaired expectoration.

Regulatory References

European Medicines Agency (EMA) assessment

Eligibility and Restrictions for Use

Who Can and Cannot Use Spasmo-Mucosolvan

Official regulatory documents define the population eligibility for this combination medicine (Ambroxol and Clenbuterol) by establishing absolute prohibitions, restrictions, and conditional use criteria.

Absolute Contraindications (Must Not Use)

Condition or Population	Restriction Basis
Cardiovascular Conditions	Strictly prohibited for individuals with Thyrotoxicosis, Tachyarrhythmia, Severe Cardiac Arrhythmia, or Idiopathic Hypertrophic Subaortic Stenosis (due to the Clenbuterol component).
Hypersensitivity	Prohibited for patients with known allergy to Ambroxol, Clenbuterol, or other sympathomimetic amines.
Pregnancy Near Term	Contraindicated due to the risk of inhibiting labor (tocolytic effect).

Restricted or Conditional Use

Population or Condition	Regulatory Status
Children	Use not established or contraindicated below a specific minimum age threshold (varies by region).
Pregnancy/Lactation	Not recommended during the first trimester of pregnancy or by nursing mothers.
Organ/Metabolic Function	Use with caution in patients with severe Hepatic or Renal Impairment, Uncontrolled Diabetes Mellitus, or a history of Gastric/Duodenal Ulceration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interaction profile for Spasmo-Mucosolvan (Ambroxol hydrochloride and Clenbuterol hydrochloride), based on regulatory requirements for its active components.

Pharmacodynamic Interaction Restrictions

Co-administration with non-selective beta-blockers is officially contraindicated by regulatory agencies. This restriction is due to the non-selective beta-blockers antagonizing the core bronchodilating effect of the Clenbuterol component, which can lead to severe pharmacological antagonism and potential worsening of respiratory function.

Interaction Type	Interacting Agent	Official Constraint
Potentiation Risk	Monoamine Oxidase Inhibitors (MAOIs)	Use requires caution due to the risk of potentiating vascular effects.
Potentiation Risk	Tricyclic Antidepressants (TCAs)	Can potentiate the cardiovascular effects of the Clenbuterol component.
Additive Effects	Other Sympathomimetic Agents	Increased risk of shared cardiovascular adverse effects.

Population-Specific Interaction Caution

Regulatory documentation notes that concurrent use with non-potassium-sparing diuretics may increase the risk of hypokalemia, or low serum potassium levels, associated with the beta2-agonist component. Furthermore, official sources indicate that the Ambroxol component has no documented clinically relevant unfavourable interaction profile with other medications, confirming a low pharmacokinetic risk for this ingredient.

Mechanism of Action

Spasmo-Mucosolvan is a fixed-dose combination containing Ambroxol and Clenbuterol.

Ambroxol primarily functions as a secretagogue and mucokinetic agent. Its action is centered on the Type II pneumocytes where it stimulates the synthesis and release of pulmonary surfactant. This increase in surfactant reduces the surface tension and adhesiveness of the respiratory tract lining fluid. Additionally, Ambroxol is posited to increase the activity of the lysosomal enzyme glucocerebrosidase (GCase), leading to increased lysosomal exocytosis, which contributes to the thinning and subsequent transport of airway secretions.

Clenbuterol acts as a beta2-adrenergic receptor agonist, binding to beta2-receptors located on the smooth muscle cells of the bronchial tree. This interaction activates the stimulatory G-protein ( G s), initiating the downstream cascade of adenylyl cyclase activation and increased intracellular concentration of cyclic adenosine monophosphate (cAMP). Elevated cAMP activates Protein Kinase A (PKA), which subsequently phosphorylates target proteins, leading to a reduction in intracellular Ca^2+ concentration and the inactivation of myosin light-chain kinase. This intracellular modulation results in the relaxation of bronchial smooth muscle cells, yielding a system-level increase in airway diameter.

Dosage and Administration Information

How to Use Spasmo-Mucosolvan

Spasmo-Mucosolvan, a fixed-dose combination containing Ambroxol and Clenbuterol, is approved exclusively for oral administration and is supplied as tablets and an oral solution or syrup. The dosing schedule is defined based on age and the specific formulation used.

Standard Labeled Dosing Regimens

The typical daily regimen is a divided-use schedule to maintain consistent concentration, with doses taken multiple times throughout the day. The maximum daily intake is explicitly defined for both available forms.

Population & Form	Typical Maintenance Dose	Maximum Daily Limit
Adult Tablets	1 tablet twice daily (morning and evening)	Must not exceed 4 tablets daily
Oral Solution	15 ml to 20 ml two to three times daily	Must not exceed 80 ml total solution

Administration Context and Adjustments

Official instructions stipulate specific conditions for proper intake. The tablets should generally be taken with meals and accompanied by adequate fluid to facilitate absorption. The oral solution should also be taken after meals. Furthermore, patients are generally instructed not to take the oral solution while lying down.

Population-Specific Use

For pediatric patients, the oral solution is utilized with specific volumes assigned to different age bands, such as 2.5 ml or 5 ml per dose, administered two to three times daily. A critical requirement is the need for dose reduction or the extension of the interval between doses for individuals with known renal or severe hepatic impairment. In the event that a dose is missed, standard practice suggests skipping that intake if it is almost time for the next scheduled dose, and never taking a double amount to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Spasmo-Mucosolvan

Evidence for Symptom Management in Acute and Chronic Airway Conditions

Research related to Spasmo-Mucosolvan, which combines a bronchodilator and a secretolytic agent, examined conditions characterized by airway narrowing and thick, sticky mucus. Studies explored how symptoms evolved in adult populations with acute and chronic respiratory tract diseases, including those with Chronic Obstructive Lung Disease (COLD). These investigations included Randomized Controlled Trials (RCTs) and drew upon Systematic Reviews to provide context for the fixed-dose combination structure.

The outcomes measured in these trials included patient-reported outcomes describing perceived discomfort, focusing specifically on the evaluation of difficulty of expectoration and cough frequency. Research also monitored mucociliary clearance metrics—the speed at which the body clears mucus. The available evidence contributes to context regarding symptom patterns in the studied populations.

Long-Term Evidence and Management of Chronic Disease

Long-term effects are not fully established. Studies related to the medicine’s components, particularly the secretolytic agent, have explored its use in the management of chronic conditions, specifically examining the frequency of acute exacerbations. Research examined patient responses over defined time intervals that extend beyond short-term use.

In research scenarios involving chronic use, specialized pharmacokinetic (PK) studies were conducted. Data describe patterns related to how the body processes the fixed combination, including findings that the Clenbuterol component was observed to accumulate during repeated, multiple-dose administration, while the Ambroxol component was not. It is not fully established how this observed pattern relates to long-term outcomes in efficacy research.

Evidence in Special Populations

Research examined the combined agents in different populations, including pediatric patients (children). However, data for this group remain insufficient for drawing robust conclusions. Studies exploring this younger population are often limited in scope, and evidence quality varies across studies. The results apply only to the populations studied, and long-term effects for these subgroups are not fully established.

Limitations of the Research Landscape

Research provides context but not individual predictions. The evidence landscape has several identified limitations: follow-up durations were limited in many initial studies, meaning the long-term effects of the combination are not fully established. Also, sample sizes were often modest, and data for certain groups—particularly children—remain insufficient, hindering the ability to draw comprehensive conclusions about specific patient outcomes.

Key Studies & References

WHO ATC Index: Ambroxol (R05CB06) - World Health Organization Collaborating Centre for Drug Statistics Methodology

Frequently Asked Questions (FAQ)

Common questions about Spasmo-Mucosolvan (FAQ)

Q: Can Spasmo-Mucosolvan be taken by children?

Regulatory documents indicate that specific dosing regimens for the oral solution are defined for pediatric patients, often categorized by age band. However, official information may also specify a minimum age cutoff for use or state caution due to insufficient data. The determination of appropriate use, based on the child’s age and condition, remains a clinical decision.

Q: What happens if I accidentally take more Spasmo-Mucosolvan than recommended?

Official drug information sheets specify maximum daily limits. If an overdose is suspected or has occurred, the general regulatory advice is to seek immediate medical attention. The administration instructions are designed to keep use within the authorized limits.

Q: What is the difference between Spasmo-Mucosolvan and a regular cough syrup?

Spasmo-Mucosolvan is officially classified as a fixed-dose combination (FDC) agent. This means it combines two distinct medicinal actions: a bronchodilator (to relax the airways) and a secretolytic (mucus thinner) to clear secretions. This dual mechanism addresses two concurrent respiratory issues, which is often different from a single-ingredient cough syrup.

Q: Are there different strengths or formulations of Spasmo-Mucosolvan?

According to the official product information, Spasmo-Mucosolvan is supplied in different dosage forms, including both tablets and an oral solution or syrup. The specific strengths of the active ingredients within these different forms are defined in the product's regulatory documents.

Q: Is it possible to become dependent on Spasmo-Mucosolvan?

Official warnings about dependency are primarily associated with certain historical formulations of the product that contained the opioid component, propoxyphene. For the current Ambroxol/Clenbuterol combination, dependence is not generally listed. The duration of use is determined by the prescriber.

Q: Can I take Spasmo-Mucosolvan if I am taking medication for anxiety?

Regulatory documents state that caution is required if the medicine is taken with specific classes of older mood disorder medications, such as Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs). This is due to the potential risk of increasing cardiovascular effects. Reviewing the interaction profile with a healthcare provider is generally recommended for any specific co-administered medicine.

Q: What are the known potential interactions with heart medications?

Official product information strictly contraindicates co-administration with non-selective beta-blockers. Caution is also required when used alongside other sympathomimetic agents or certain diuretics, as the bronchodilator component can affect the cardiovascular system and potentially cause low serum potassium levels (hypokalemia).

Q: Is Spasmo-Mucosolvan the same as Mucosolvan?

The official identity of Spasmo-Mucosolvan is a fixed-dose combination of two active ingredients: Ambroxol and Clenbuterol. This is distinct from Mucosolvan, which is typically a single-ingredient product containing only Ambroxol.

Q: Does Spasmo-Mucosolvan help with dry cough or wet cough?

The medicine is indicated for respiratory conditions specifically associated with the presence of excessive, tenacious (thick) mucus and airway narrowing. These are typical features of a productive or wet cough.

Q: How quickly should I expect Spasmo-Mucosolvan to start working?

While the specific time to onset of action (Tmax) may not be listed for the combination, the active components are absorbed relatively quickly after oral administration. The bronchodilator component is understood to begin its action quickly after administration, which contributes to the relief of bronchial spasm.

Q: Does Spasmo-Mucosolvan cause drowsiness?

The regulatory documents list central nervous system effects such as nervousness and headache due to the bronchodilator component. While drowsiness itself may not be explicitly listed, altered alertness is a possibility with similar medications, and individual reactions can vary.

Q: How long does the effect of one dose of Spasmo-Mucosolvan usually last?

The standard dosing schedule found in official documents, which typically involves taking the medicine multiple times a day, provides an indirect indication of the duration of the drug’s therapeutic effect. This schedule is designed to maintain consistent concentration for effective relief.

Q: Can Spasmo-Mucosolvan be used to treat asthma symptoms?

The medicine is officially indicated for respiratory diseases characterized by thick mucus and airway narrowing. These are symptoms that can be associated with conditions like Chronic Obstructive Lung Disease (COLD). The specific regulatory label indicates the approved uses for this combination.

Q: Is Spasmo-Mucosolvan safe to take if I have high blood pressure?

Official warnings state that the use of this medication requires caution in patients with high blood pressure (hypertension). It is strictly contraindicated (prohibited) for individuals with severe cardiovascular conditions, such as Tachyarrhythmia, due to the effects of the bronchodilator component.

Q: Can Spasmo-Mucosolvan be crushed or broken if it's a tablet?

Official regulatory guidance states that standard tablets should generally be swallowed whole unless the product is specifically designed to be broken or crushed. Altering the tablet can change how the medicine is absorbed and is a reason why altering the tablet is generally not authorized for non-scored combination products.

Q: What is Spasmo-Mucosolvan used for besides cough?

The medicine is used to ease breathing difficulties that result from both bronchial spasms (airway narrowing) and the presence of thick, sticky mucus. It provides relief by addressing these two underlying physical issues simultaneously.

Q: Can I drive or operate machinery after taking Spasmo-Mucosolvan?

Official warnings advise caution for activities like driving or operating machinery. This is because side effects such as tremors or dizziness may occur, and these effects could potentially impair a person's ability to perform such tasks, especially when starting treatment.

Q: What should I do if my symptoms get worse while taking Spasmo-Mucosolvan?

Regulatory documents state that consulting a healthcare professional is necessary if symptoms worsen or fail to improve. Consultation is also advised if the expected improvement is not observed within the designated treatment duration.

Q: Is there a warning about taking Spasmo-Mucosolvan with alcohol?

Official drug labels typically advise caution or avoidance regarding the consumption of alcohol while using this medicine. Alcohol can potentially increase the risk or severity of some central nervous system and cardiovascular side effects associated with the bronchodilator component.

Q: How long can I continue taking Spasmo-Mucosolvan before needing a doctor's checkup?

Regulatory instructions define the maximum recommended duration for use, particularly for short-term treatment. A doctor should be consulted if symptoms persist or fail to improve beyond a specific, designated time frame (e.g., typically 5 to 7 days).

Q: What is the difference in effect between the syrup and tablet form?

While the overall intended therapeutic effect is the same, liquid and solid formulations may differ in their absorption rate and subsequent onset of action. The choice between the syrup and tablet form often depends on patient preference and specific dosing requirements.

Q: Does Spasmo-Mucosolvan cause difficulty sleeping?

Official side effect lists commonly include reactions such as insomnia or sleep disturbance. This is a possible effect due to the stimulating properties of the bronchodilator component (Clenbuterol).

Q: Is it safe to use Spasmo-Mucosolvan with other cold and flu medicines?

Regulatory warnings specifically advise caution against using this medicine with other sympathomimetic agents. Many common cold and flu products contain these agents, and combining them with Spasmo-Mucosolvan increases the risk of additive cardiovascular adverse effects.

How should Spasmo-Mucosolvan be stored and disposed of?

Storage and Disposal of Spasmo-Mucosolvan

Spasmo-Mucosolvan must be stored according to official regulatory requirements to maintain its stability and effectiveness.

Storage Conditions

The medicine does not require special temperature conditions but must be stored in a dry and cool place.

Protection: Keep the product in its original container and protect from heat and direct sunlight.
Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.
Stability: Do not use after the expiry date. Liquid forms typically have a limited shelf-life after opening (e.g., 1 month).

Disposal Instructions

Official disposal guidelines require that expired or unused medicine must not be flushed into wastewater or placed in household waste.

Procedure: Any unused product must be discarded by returning it to a pharmacy or by following local requirements for the disposal of pharmaceutical waste.

Spasmo-Mucosolvan